BioCentury | Dec 20, 2010
Company News

Cancer Targeted Technology, Bayer deal

...The companies will collaborate to optimize a PET imaging agent based on Cancer Targeted Technology's enzyme inhibitor scaffold...
...scaffold which targets the prostate-specific membrane antigen ( PSMA ; FOLH1 ; GCPII ) biomarker. Cancer Targeted Technology...
...agent into clinical development. Bayer has a six to 12 month option period to license Cancer Targeted Technology's...
Items per page:
1 - 1 of 1
BioCentury | Dec 20, 2010
Company News

Cancer Targeted Technology, Bayer deal

...The companies will collaborate to optimize a PET imaging agent based on Cancer Targeted Technology's enzyme inhibitor scaffold...
...scaffold which targets the prostate-specific membrane antigen ( PSMA ; FOLH1 ; GCPII ) biomarker. Cancer Targeted Technology...
...agent into clinical development. Bayer has a six to 12 month option period to license Cancer Targeted Technology's...
Items per page:
1 - 1 of 1